Guldiken Ipek N, Gurler Gokhan, Delilbasi Cagri
Int J Oral Maxillofac Implants. 2021 Nov-Dec;36(6):e159-e165. doi: 10.11607/jomi.8929.
Conscious sedation in oral surgical procedures provides comfort both for patients and practitioners. Midazolam is a sedative agent commonly used in this manner. Dexmedetomidine is also a decent sedative agent, with its analgesic and mild respiratory effects, which is usually preferred in intensive care units. Dexmedetomidine has been recently used in dental surgeries. This study aimed to investigate the analgesic and respiratory properties of midazolam and dexmedetomidine in conscious sedation during dental implant procedures and to compare these two drugs in terms of ease of use and comfort of dental implant operation.
This study was a prospective double-blind randomized controlled study. The patients who needed dental implant placement were divided into two randomized groups for either midazolam or dexmedetomidine. The amount of sedative agent used, duration of the procedure, onset of sedation, use of additional same sedative agent, and occurrence of desaturation were recorded. Hemodynamic and respiratory variables (mean blood pressure, heart rate, oxygen saturation, and respiratory rate) were recorded every 10 minutes, starting immediately before the loading dose until the end of the procedure. Patients completed a Likert scale for their satisfaction, and patient pain was scored using the numeric rating scale postoperatively. The amount of painkiller usage was recorded and reported. All surgical procedures were performed by the same surgeon, and all recordings were taken by an anesthesiology technician; both were blinded for the randomization. Descriptive and bivariate statistics were computed, and the P value was set at < .05.
This study included patients who were scheduled for two to five dental implant insertions to either arch under conscious sedation. A total of 163 dental implants were inserted into 43 patients. Patients receiving dexmedetomidine had lower pain, higher satisfaction with the procedure, and less desaturation (P = .002). The onset of sedation was more rapid with midazolam (P = .001). The number of implants according to drugs did not differ statistically. On the other hand, the mean operation time was 52.09 ± 20.12 minutes in the dexmedetomidine group and 87.14 ± 26.15 minutes in the midazolam group (P = .001). No significant difference was found for retrograde amnesia and preference of sedative between midazolam and dexmedetomidine.
Dexmedetomidine is a good alternative to midazolam for conscious sedation during dental implant procedures, with its better analgesic property and minimal respiratory side effects.
口腔外科手术中的清醒镇静可为患者和从业者提供舒适感。咪达唑仑是常用于此的镇静剂。右美托咪定也是一种不错的镇静剂,具有镇痛和轻度呼吸作用,通常在重症监护病房中更受青睐。右美托咪定最近已用于牙科手术。本研究旨在调查咪达唑仑和右美托咪定在牙种植手术清醒镇静中的镇痛和呼吸特性,并在易用性和牙种植手术舒适性方面比较这两种药物。
本研究是一项前瞻性双盲随机对照研究。需要进行牙种植的患者被随机分为两组,分别接受咪达唑仑或右美托咪定。记录所用镇静剂的量、手术持续时间、镇静起效时间、额外使用相同镇静剂的情况以及去饱和的发生情况。从负荷剂量前即刻开始,每10分钟记录一次血流动力学和呼吸变量(平均血压、心率、血氧饱和度和呼吸频率),直至手术结束。患者完成一份关于满意度的李克特量表,并在术后使用数字评分量表对患者疼痛进行评分。记录并报告止痛药的使用量。所有手术均由同一位外科医生进行,所有记录均由麻醉技术人员完成;两者均对随机分组情况不知情。计算描述性和双变量统计数据,P值设定为<0.05。
本研究纳入了计划在清醒镇静下为任一牙弓植入两至五颗牙种植体的患者。共为43例患者植入了163颗牙种植体。接受右美托咪定的患者疼痛较轻、对手术的满意度较高且去饱和情况较少(P = 0.002)。咪达唑仑的镇静起效更快(P = 0.001)。根据药物分组的种植体数量在统计学上无差异。另一方面,右美托咪定组平均手术时间为52.09±20.12分钟,咪达唑仑组为87.14±26.15分钟(P = 0.001)。咪达唑仑和右美托咪定在逆行性遗忘和镇静剂偏好方面无显著差异。
在牙种植手术的清醒镇静中,右美托咪定是咪达唑仑的良好替代药物,具有更好的镇痛性能和最小的呼吸副作用。